Japanese deal for BioFocus
BioFocus, based at the heart of the Cambridge UK science &
technology cluster, is partnering Japanese pharmaceutical giant Ono
in a drug discovery programme targeting disorders of the Central
nervous system (CNS).
The Chesterford Research Park company - Galapagos' service
division - has signed a new alliance agreement with Ono
Pharmaceutical Co., Ltd. of Osaka.
BioFocus will use its drug discovery platform to deliver leads
and clinical candidates for its client. Financial details of the
collaboration were undisclosed.
Dr Chris Newton, SVP Galapagos Services and managing director of
BioFocus said: "We are delighted to have this new agreement, which
is the first drug discovery program with this, a most valued,
"This project plays to BioFocus' historic strengths and the
expanding breadth and depth of this partnership is testament to a
tried and trusted relationship
To continue reading this article click
Source - www.businessweekly.co.uk